News | July 08, 2025
Everest Medicines progresses in AI-powered mRNA platform at 2025 R&D day
The company showcased three core programs developed through this platform
The company showcased three core programs developed through this platform
Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states
The audit has been concluded with no major observations
Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone
Opaganib has shown potential in enhancing ARPI treatment by blocking multiple enzymes involved in cancer cell survival.
Loteprednol Etabonate Ophthalmic Gel, 0.38% is a corticosteroid indicated for the treatment of postoperative inflammation and pain following ocular surgery
ISG acknowledged Indegene's strengths in implementing holistic creative workflows, interoperability via robust integration with tech ecosystems
The pet dog population alone is expected to increase from 21.4 million in 2019 to 51.5 million by 2028
Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME
Star Health Insurance is modernising its claims ecosystem to be future-ready
Subscribe To Our Newsletter & Stay Updated
